Genetic Signatures Ltd
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company.
The business
Genetic Signatures Limited is an Australia-based specialist molecular diagnostics (MDx) company. The Company's principal activities include research and commercialization of identifying individual genetic signatures to identify diseases and the sale of associated products into the diagnostic and research marketplaces. The Company is focused on the development and commercialization of its platform technology, 3base. Its MDx 3base platform technology provides high-volume hospitals and pathology laboratories with the ability to screen for an array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. It designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen brand. Its products include EasyScreen Pan-Enteric Detection Kit, EasyScreen STI Genital Pathogen Detection, EasyScreen Viral Meningitis Detection Kit, and others.
Small Caps Research
No research on Genetic Signatures Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise GSS based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
ASX biotech stocks benefiting from the COVID-19 story
Normally investors shun speculative plays in times of market uncertainties, but that’s not been the case with ASX-listed life science stocks across the drug, diagnostics and device sectors. Naturally, the biotechs drawing a connection with fighting or detecting the virus – spurious or otherwise – have seen their valuations soar. Not that investor interest is […]
Genetic Signatures applies to market coronavirus test kit throughout UK and EU
Molecular diagnostics company Genetic Signatures (ASX: GSS) has submitted a European CE in vitro diagnostics registration application for its new 3base EasyScreen coronavirus detection kit. The kit complements the company’s existing EasyScreen respiratory pathogen detection kit which identifies 14 common respiratory pathogens including influenza A and B, rhinovirus and M. pneumoniae and allows a large […]
Genetic Signatures receives green light to market pathogen detection kit in Europe
Molecular diagnostics company Genetic Signatures (ASX: GSS) has received CE-IVD registration, paving the way for the sale of its “EasyScreen” Respiratory Pathogen Detection Kit in Europe. The detection kit can identify 14 common respiratory pathogens, including Influenza A & B, Rhinovirus and M. pneumoniae. The kit allows for rapid detection of pathogens in up to […]
Genetic Signatures secures ‘major’ sales contract for EasyScreen respiratory technology
Molecular diagnostics company Genetic Signatures (ASX: GSS) has announced a major new contract with a large Australian pathology service provider and release of two new products. Genetic Signatures secured the contract with an Australian pathology service provider and expects its new customer to conduct as many as 1,000 tests per day, depending on the severity […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.